Aripiprazole

Generic Name
Aripiprazole
Brand Names
Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
Drug Type
Small Molecule
Chemical Formula
C23H27Cl2N3O2
CAS Number
129722-12-9
Unique Ingredient Identifier
82VFR53I78
Background

Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...

Indication

Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...

Associated Conditions
Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
Associated Therapies
Monotherapy

Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2010-07-01
Last Posted Date
2016-05-26
Lead Sponsor
University of Copenhagen
Target Recruit Count
136
Registration Number
NCT01154829
Locations
🇩🇰

Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup, Glostrup, Denmark

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-06-23
Last Posted Date
2015-04-02
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
252
Registration Number
NCT01149655
Locations
🇨🇳

Study Site, Taoyuan County, Taiwan

A Long-Term, Open-Label, Study on Schizophrenia

First Posted Date
2010-05-25
Last Posted Date
2013-01-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1210
Registration Number
NCT01129674
Locations
🇺🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vinnytsya, Ukraine

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia

Phase 3
Completed
Conditions
Interventions
First Posted Date
2010-05-25
Last Posted Date
2020-01-06
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
709
Registration Number
NCT01129882

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.

First Posted Date
2010-05-13
Last Posted Date
2016-02-08
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
524
Registration Number
NCT01122927
Locations
🇺🇦

Study Site, Vinnytsya, Ukraine

🇺🇦

Study Site 2, Kharkiv, Ukraine

🇺🇦

Study Site 1, Kharkiv, Ukraine

Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis

Phase 4
Conditions
Interventions
First Posted Date
2010-05-07
Last Posted Date
2014-10-03
Lead Sponsor
Anne Katrine Pagsberg
Target Recruit Count
300
Registration Number
NCT01119014
Locations
🇩🇰

Aalborg Psychiatric Hospital, Aalborg, Denmark

🇩🇰

Psychiatric Centre Copenhagen, Rigshospitalet, Copenhagen, Denmark

🇩🇰

Hillerød Hospital, Hillerød, Denmark

and more 6 locations

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

First Posted Date
2010-04-27
Last Posted Date
2021-10-26
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
237
Registration Number
NCT01111552
Locations
🇷🇴

Study Site 1, Bucuresti, Romania

🇷🇴

Study Site 2, Bucuresti, Romania

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

First Posted Date
2010-04-27
Last Posted Date
2021-12-21
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
137
Registration Number
NCT01111565
Locations
🇿🇦

Study Site 1, Cape Town, South Africa

🇿🇦

Study Site 2, Cape Town, South Africa

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

First Posted Date
2010-04-27
Last Posted Date
2021-10-20
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
211
Registration Number
NCT01111539
Locations
🇮🇳

Study Site 1, Ahmedabad, Gujarat, India

🇮🇳

Study Site 2, Ahmedabad, Gujarat, India

© Copyright 2024. All Rights Reserved by MedPath